neuroone medical technologies corporation operates as a medical technology company. it focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (ceeg) and stereoelectroencephalography (seeg) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, parkinson's disease, dystonia, essential tremors, and other related brain related disorders. the company is based in eden prairie, minnesota.
Company profile
Ticker
NMTC
Exchange
Website
CEO
David A. Rosa
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Original Source Entertainment, Inc.
SEC CIK
Corporate docs
IRS number
270863354
NMTC stock data
Latest filings (excl ownership)
8-K
NeuroOne® Initiates Limited Commercial Launch of OneRF™ Ablation System
26 Mar 24
8-K
Submission of Matters to a Vote of Security Holders
15 Mar 24
8-K
NeuroOne® Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
13 Feb 24
10-Q
2024 Q1
Quarterly report
13 Feb 24
S-8
Registration of securities for employees
31 Jan 24
ARS
2023 FY
Annual report to shareholders
29 Jan 24
DEF 14A
Definitive proxy
29 Jan 24
424B5
Prospectus supplement for primary offering
5 Jan 24
S-8
Registration of securities for employees
15 Dec 23
10-K
2023 FY
Annual report
15 Dec 23
Transcripts
NMTC
Earnings call transcript
2024 Q1
13 Feb 24
NMTC
Earnings call transcript
2023 Q4
14 Dec 23
NMTC
Earnings call transcript
2023 Q3
14 Aug 23
NMTC
Earnings call transcript
2023 Q2
11 May 23
NMTC
Earnings call transcript
2023 Q1
14 Feb 23
NMTC
Earnings call transcript
2022 Q4
13 Dec 22
NMTC
Earnings call transcript
2022 Q3
14 Aug 22
NMTC
Earnings call transcript
2022 Q2
14 May 22
NMTC
Earnings call transcript
2022 Q1
14 Feb 22
NMTC
Earnings call transcript
2021 Q4
15 Dec 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 23 | Sep 22 | Sep 21 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 5.32 mm | 5.32 mm | 5.32 mm | 5.32 mm | 5.32 mm | 5.32 mm |
Cash burn (monthly) | (no burn) | 236.49 k | 1.05 mm | 998.51 k | 967.61 k | 1.07 mm |
Cash used (since last report) | n/a | 1.62 mm | 7.23 mm | 6.84 mm | 6.63 mm | 7.36 mm |
Cash remaining | n/a | 3.70 mm | -1.91 mm | -1.52 mm | -1.31 mm | -2.04 mm |
Runway (months of cash) | n/a | 15.7 | -1.8 | -1.5 | -1.4 | -1.9 |
Institutional ownership, Q2 2023
20.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 14 |
Opened positions | 1 |
Closed positions | 2 |
Increased positions | 3 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 1.01 bn |
Total shares | 5.39 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Manchester Management | 4.50 mm | $7.16 mm |
Vanguard | 440.25 k | $528.30 mm |
Mayo Clinic | 181.75 k | $218.11 mm |
Geode Capital Management | 128.90 k | $154.68 mm |
SG Americas Securities | 53.81 k | $65.00 k |
STT State Street | 35.90 k | $43.08 mm |
NTRS Northern Trust | 19.93 k | $23.92 mm |
Princeton Global Asset Management | 16.83 k | $20.20 mm |
Tower Research Capital | 10.23 k | $12.28 mm |
Nemes Rush | 433.00 | $520.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
21 Apr 24 | Rosa David A | Common Stock | Payment of exercise | Dispose F | No | No | 1.15 | 19,673 | 22.62 k | 1,164,836 |
21 Apr 24 | Christianson Mark | Common Stock | Payment of exercise | Dispose F | No | No | 1.15 | 2,030 | 2.33 k | 323,204 |
21 Apr 24 | Steve Mertens | Common Stock | Payment of exercise | Dispose F | No | No | 1.15 | 7,250 | 8.34 k | 176,661 |
31 Mar 24 | Rosa David A | Common Stock | Payment of exercise | Dispose F | No | No | 1.2 | 2,239 | 2.69 k | 1,184,509 |
31 Mar 24 | Christianson Mark | Common Stock | Payment of exercise | Dispose F | No | No | 1.2 | 90 | 108.00 | 325,234 |
News
NeuroOne Earlier Announced First Implant Of OneRF Ablation Electrodes
9 Apr 24
12 Health Care Stocks Moving In Monday's Intraday Session
11 Mar 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
14 Feb 24
12 Health Care Stocks Moving In Tuesday's After-Market Session
13 Feb 24
Earnings Scheduled For February 13, 2024
13 Feb 24
Press releases
NeuroOne® Announces First Implant of OneRF™ Ablation Electrodes
9 Apr 24
NeuroOne® CEO Dave Rosa Featured on Fox Business Network's Varney & Co.
4 Apr 24
NeuroOnes's Innovative Electrode Brain Monitoring Seeks To Provide Insights Into Neurological Disorders
28 Mar 24
NeuroOne Medical Technologies' (NASDAQ: NMTC) Innovative Brain Monitoring Tech Developing And Commercializing Electrodes
11 Mar 24
NeuroOne® to Participate in the 36th Annual Roth Conference
8 Mar 24